Eli Lilly (LLY) has signed a research collaboration with Hong Kong-listed Metis TechBio (7666.HK) that Reuters reported on Monday, October 19, is worth up to $1.1 billion. The two companies will work on lipid nanoparticles (LNPs), the tiny fat shells that carry genetic medicines into cells, using Metis’s AI platform to steer them toward specific tissues.
That $1.1 billion headline needs a footnote. Metis gets an upfront payment in the low double-digit millions of dollars, and the rest arrives only if the work clears development, regulatory and commercial milestones.
The Fine Print on Lilly’s $1.1 Billion Deal
- Upfront: low double-digit millions (the exact figure wasn’t disclosed)
- Milestones: up to about $1.1 billion, all contingent
- Royalties: tiered, at a single-digit percentage of net sales
- Stage: research and discovery, with no named drug candidate or timeline
- Partner: Metis only listed in Hong Kong on May 13
Sizing the Deal Against Lilly’s Lab Budget
Lilly spent $14.60 billion on R&D over the last 12 months, up from $9.31 billion in 2023. That works out to about $40 million a day.
The upfront payment wasn’t disclosed, but “low double-digit millions” puts it below $100 million, which is under 0.7% of Lilly’s annual R&D. Even if every milestone pays out, the full $1.1 billion equals about 7.5% of one year’s R&D, spread across years of development. Lilly’s dealmaking usually runs far bigger: its second-quarter results carried $3.03 per share of acquired IPR&D charges in a single quarter.
Why Lilly Keeps Buying Delivery Tech
The pattern matters more than the price. In May, Lilly bought Engage Bio for up to $202 million for its non-viral DNA delivery platform. In September, it signed QurCan Therapeutics to carry genetic medicines into the brain and nerves, with milestones of up to $237 million per program. Metis is the third delivery bet in about five months.
Conventional LNPs given intravenously tend to accumulate in the liver, which makes efficient delivery to the heart, lungs or muscle a major challenge. That’s what “tissue-specific” means in Monday’s announcement. Lilly is pursuing several delivery platforms through acquisitions and research collaborations.
What the Metis Deal Means for Lilly Stock
The announcement does not disclose the deal’s effect on Lilly’s 2026 earnings. What Lilly gets is an option on moving genetic medicines beyond the liver, one of the hardest open problems in that field. At an upfront below $100 million against $14.60 billion in annual R&D, that’s a cheap option, and it fits a five-month pattern rather than standing alone. The number that matters more comes on October 29, when Lilly reports third-quarter results and shows how much its deal spree added to acquired IPR&D after the second quarter’s $3.03 a share.
Want to see how fast Lilly’s research budget is growing, quarter by quarter? You can pull up the same R&D data, plus analysts’ forecasts for the years ahead, on TIKR for free. Learn more here.
So what is Eli Lilly stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what LLY stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Value Eli Lilly and Company for free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
